About the Report
Osteoporosis indicates a chronic disease in which an individual loses bone mass density majorly in the hip or spine. Treatment for osteoporosis involves several oral drugs and injectable. According to the National Osteoporosis Foundation, there has been a significant rise in osteoporosis prevalence among postmenopausal women due to calcium deficiency. This is one of the key factors fuelling the demand for anti-osteoporosis therapy and fracture healing.
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights offers insights about key factors driving demand for anti-osteoporosis therapy and fracture healing. The report tracks global sales of anti-osteoporosis therapy and fracture healing drugs in 20+ high-growth markets, where major traction is being witnessed in North America, followed by Europe.
How Does the Historic and Future Outlook of Anti-Osteoporosis Therapy And Fracture Healing Match Up?
Oral drugs are most common in anti-osteoporosis therapy and fracture healing. The rising demand for non-invasive therapeutics has been contributing towards the expansion of the market. An increasing number of pharmaceutical producers are expected to focus on expanding their manufacturing capacity. Countries such as India and China are continuously expanding their manufacturing units. According to the India Brand Equity Foundation, Indian pharmaceutical business is leading supplier of global vaccines, accounting for 50% market share and 40% of global generic drugs.
Increasing investment in innovation and new product launches is a result of scientific development opportunities for product effectiveness and minimum complications. Their efforts have been leading to anti-osteoporosis therapy and fracture healing market expansion. For instance, on October 2020 Amgen Inc. announced a 17% increase of profit from the previous year as a result of high sales of osteoporosis drug and psoriasis medication.
According to Future Market Insight’s analysis, the anti-osteoporosis therapy and fracture healing market expanded at 3.8 % CAGR from 2015 to 2019.
Large scale closures and shutdown have led to a halt in manufacturing activities across the globe impacting anti-osteoporosis therapy and fracture healing market growth. Leading biopharmaceutical firms are currently focusing on developing coronavirus cure, resulting in the delay in research and development activities.
There has been a significant decline in hospital patient visits during the pandemic, which is expected to delay anti-osteoporosis therapy and fracture healing market growth. Future Market Insights (FMI) forecasts the market to progress at an impressive 5% CAGR through 2030.
Will Demand for Anti-Osteoporosis Therapy And Fracture Healing Increase with Rising Number of Trauma Centers?
Increasing expenditure towards healthcare has led to the expansion of healthcare infrastructure and resulted in increasing the number of healthcare facilities. The rise in the number of trauma centers will lead to increasing accessibility of anti-osteoporosis therapy and fracture healing and hence driving the market growth.
For instance, in 2020 out of 1154 operating trauma centers in the U.S. 190 are estimated to be level 1 trauma centers and 263 are under the category of level 2 trauma centers. Therefore, increasing cases of road accidents and patients receiving treatment has grown simultaneously.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
How is the Market Benefiting from Advent of New Drug Class?
Bisphosphonates, estrogen therapy, and selective estrogen receptor modulators (SERMs) are considered key drug classes within the global anti-osteoporosis therapy and fracture healing market. However, these drugs were invented decades ago and patents of most drugs are expired or expected to expire during the forecast period. Hence, the introduction of a new drug class with higher efficiency as compared other drug is expected to have a positive impact on global anti-osteoporosis therapy and fracture healing market growth.
How big is the Opportunity in the U.S. for Anti-osteoporosis Therapy and Fracture Healing?
FMI has projected North America to remain the most lucrative market throughout the forecast period. One of the key factors supporting expansion is increasing compliance with regulatory requirements.
The increasing frequency of approval and commercialization of the drug in the U.S. is expected to boost anti-osteoporosis therapy and fracture healing market. Also, the majority of the key players of anti-osteoporosis therapy and fracture healing market have its headquarters based in the U.S.
The increasing demand for diagnosis and treatment is expected to create opportunities for growth. Furthermore, the cost of drugs is comparatively higher in the country such as the U.S., leading to the high-profit margin companies operating in the country.
Furthermore, the U.S. remains one of the largest markets for pharmaceuticals in the world, which invariably makes it a lucrative pocket for anti-osteoporosis therapy and fracture healing players. The market in the U.S. is expected to progress at a healthy CAGR of over 6% during the forecast period.
What are the Restrains that GCC Countries Face in Anti-Osteoporosis Therapy and Fracture Healing?
There is significantly less awareness about osteoporosis and its therapeutic options available in GCC countries making it less lucrative of anti-osteoporosis therapy and fracture healing market growth. Whereas, the population of GCC countries have less purchasing power parity leading to less expenditure towards healthcare
Unavailability of skilled medical professionals and poor healthcare infrastructure leads to less diagnosis and treatment rate. The anti-osteoporosis therapy and fracture healing market in GCC countries is expected to witness sluggish growth at a CAGR of just around 3%.
What is the Contribution of Italy Market for Anti-Osteoporosis Therapy and Fracture Healing?
Italy is expected to rise 5% as a market for anti-osteoporosis therapy and fracture healing. The country has a significantly high number of geriatric population who are at the high risk of suffering from osteoporosis, making Italy a lucrative for anti-osteoporosis therapy and fracture healing market growth. Italy also has well-developed healthcare facilities with highly skilled labor catering to anti-osteoporosis therapy and fracture healing services.
The availability of advanced technology for diagnosis and treatment of osteoporosis and fracture leads to Italy having a considerable amount of more than 10% share in Europe anti-osteoporosis therapy and fracture healing market. On the other hand, favourable reimbursement scenarios make the Italy market for anti-osteoporosis therapy and fracture healing attractive for key players to penetrate and invest in the country.
How Attractive Is the China Market for Anti-Osteoporosis Therapy and Fracture Healing?
China being among the countries with the highest population rate offers impressive growth opportunities to the market. The country has also increased its manufacturing capacity over the past decade and has become the leading provider of drugs and its raw materials in anti-osteoporosis therapy and fracture healing market. Increasing per capita healthcare expenditure in China is one of the driving factors of the market.
What are the Factors Responsible for Malaysia in Anti-osteoporosis Therapy and Fracture Healing Market Growth?
Malaysia is the second leading market for anti-osteoporosis therapy and fractures healing in South Asia following India. The country is expected to exhibit growth rate of more than 3%. Malaysia is one of the attractive destinations for medical tourism with less treatment cost as compared to the U.S. or U.K.
According to MDPI, globally 21 million men and 137 million women had probability of osteoporotic fracture in 2010 and over 55% of them belong from Asia. Several studies are being conducted in Malaysia to study the risk factors associated with the condition, which is expected to have a significant impact on the market.
Which Anti-Osteoporosis Therapy and Fracture Healing Drug Type is More Preferred?
Bisphosphonates will continue accounting for over 49% of the global share among drug class through the forecast period. This is due to the rising demand for target-specific therapeutics among the patients and shift of prescription pattern towards bisphosphonates.
Share of drug class differs in key markets, the following chart presents the elucidated view of the drug class share concerning key regions. In the top 7 regions which include North America, Latin America, Europe, South Asia, East Asia, Oceania and the Middle East & Africa, the share of North America is significantly high, in comparison to other regions and among drug class bisphosphonates accounts for leading share of the market. Estrogen or Hormone Replacement Therapy is also a mass category drug class, as it holds the second position in terms of demand across all key regions.
Why Does Oral Osteoporosis Therapy and Fracture Healing Drug Exhibit Lead?
Anti-osteoporosis therapy and fracture healing market have oral drugs and injectable drugs. Where the oral drug is estimated to hold more than 65% of revenue share in anti-osteoporosis therapy and fracture healing market with increasing demand for non-invasive therapeutics.
Factors such as increasing prevalence of needle phobia and needle stick injuries are increasing demand for oral drugs into the therapeutics. On the other hand, the high cost of injectable drugs restrains its growth into the anti-osteoporosis therapy and fracture healing market.
Why is Demand from Hospital Pharmacies More?
Revenue from hospital pharmacies is expected to increase 2X by 2030-end as compared to that in 2019. Increasing prevalence of osteoporosis and trauma fractures is expected to fuel the demand for anti-osteoporosis therapy and fracture healing market during the forecast period.
Hospital pharmacies with the high number of the patient population are leading distribution channel for anti-osteoporosis therapy and fracture healing market. On the other hand, with the increasing adaption of e-commerce activities, online pharmacies will observe high growth rate in the coming decade.
Leading market players are focusing on expanding their product portfolio with product innovations and developments. Key players are also adopting merger and acquisition strategies for increasing their presence across the globe in anti-osteoporosis therapy and fracture healing market.
For instance, in December 2019 Amgen Inc. was granted marketing authorization from the European Commission (EC) for its osteoporosis drug used for treatment among postmenopausal women at high risk of fractures. On the other hand, anti-osteoporosis therapy and fracture healing market is a moderately consolidated market with less than 10 market players consisting of more than 50% of the revenue share.
Some of the leading companies operating in the market are:
- Eli Lilly and Company
- Pfizer Inc.
- Amgen Inc.
- Merck and Company, Inc.
- Novartis International AG
- F. Hoffmann La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline Plc.
*The list is not exhaustive, and only for representational purposes. Full competitive intelligence with SWOT analysis available in the report.
Scope of Report
Historical Data Available for
USD Million for Value
Key Regions Covered
North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East & Africa
Key Countries Covered
U.S., Canada, Brazil, Mexico, Argentina, Germany, Italy, France, U.K., Spain, BENELUX, Russia, India, Thailand, Indonesia, Malaysia, China, Japan, South Korea, Australia, New Zealand, GCC Countries and South Africa
Key Segments Covered
Drug Type, Route of Administration, Distribution Channel, and Region
Key Companies Profiled
Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives
Customization & Pricing
Key Questions Answered in Report
Which is the most lucrative market for anti-osteoporosis therapy and fracture healing?
The North America anti-osteoporosis therapy and fracture healing market currently holds dominance. The U.S. leads the global market for anti-osteoporosis therapy and fracture healing, with revenue expected to reach US$ 6.3 Bn by 2030.
Which drug type remains dominant for anti-osteoporosis therapy and fracture healing?
Bisphosphonates are expected to be most lucrative segment among the drug type with the increasing adaption of target-specific therapies as compared to other drugs, and the segment is expected continue to expand at a CAGR of more than 4% over the next ten years.
Which are some of the leading companies offering anti-osteoporosis therapy and fracture healing?
Some of the leading companies offering animal drug compounding are Eli Lilly and Company, Pfizer Inc., Amgen Inc., Merck and Company Inc., Novartis International AG, F. Hoffmann La Roche Ltd., Teva Pharmaceutical Industries Ltd., and GlaxoSmithKline Plc.
Which route of administration is more preferred for anti-osteoporosis therapy and fracture healing?
Oral route of administration is expected to remain most preferred. Oral medications are expected to witness stable growth in demand owing to blockbuster drug expiries, increasing cases of needlestick injuries, and rise in the adaption of combinational drugs.
Enquiry Before Buying
Is this research conducted by Future Market Insights?
Yes, the research has been conducted by expert analysts of Future Market Insights, through a combination of primary research and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Future Market Insights?
Future Market Insights follows a methodology that encompasses the demand-side assessment of the market and triangulates the same through supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions. Request a detailed methodology.
Who are the respondents for primary research?
Future Market Insights speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
What are the sources of secondary research?
Future Market Insights conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.
How can I buy this report?
Future Market Insights provides a secure online payment system to buy reports seamlessly. You can buy the report securely and safely.
Anti-osteoporosis Therapy and Fracture Healing Market by Category
- Estrogen or Hormone Replacement Therapy
Route of Administration
- Hospital Pharmacies
- Drug Stores
- Retail Pharmacies
- North America
- Latin America
- South Asia
- East Asia
- Middle East and Africa (MEA)